Amazon.com, Nvidia, Tesla, and the rest of the Magnificent Seven stocks jump as the U.S. and China reach an agreement to ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Trump's order seeks to ease regulations to compel more U.S. drug manufacturing. He also plans to assess tariffs on drug ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...